Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy

  • Get the full experience

    We save the real magic for signed-in users.

CODX US​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings
Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy

  • Get the full experience

    We save the real magic for signed-in users.

CODX US​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings

Co-Diagnostics, Inc.(CODX US)

$0.26-0.014.12%Ext:$0.26+0.000.66%(After Hours · 00:21:30 UTC)
Ask AI
Doc SearchProfileEntity StructureFinancialsChartingShort InterestEmployees

Overview

ProfileEntity Structure

Documents

SEC Filings

Co-Diagnostics, Inc.(CODX US)

$0.26-0.014.12%Ext:$0.26+0.000.66%(After Hours · 00:21:30 UTC)
Ask AI
Doc SearchProfileEntity StructureFinancialsChartingShort InterestEmployees

Overview

ProfileEntity Structure

Documents

SEC Filings

Financials & Metrics

FinancialsChartingShort InterestEmployees

Financials & Metrics

FinancialsChartingShort InterestEmployees

Co-Diagnostics, Inc. — Company Profile

Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.

Sector
Industrials
Industry
Commercial Services & Supplies
Exchange
UQ
CEO
Dwight Egan
Headquarters
Salt Lake City, UT, US
IPO Date
Jul 12, 2017
Employees
115
Website
co-dx.com

Key Metrics

Price
$1.09
Market Cap
$6.82M
Revenue (TTM)
$145.95K
Net Income (TTM)
$-9140038.00
EPS (TTM)
-4.06
P/E (TTM)
-0.14
P/B (TTM)
0.42
Dividend Yield
0.00%
ROE (TTM)
-56.97%
ROA (TTM)
-42.51%
Operating Margin
-63.09%
Beta
3.36

Dividends

Last Dividend
$0.00
Last Yield
0.00%

Summary

Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.

Website
co-dx.com
Location
Salt Lake City, UT, US
Phone801 438 1036
Employees115
CEODwight Egan
Sector
Industrials
Industry
Commercial Services & Supplies
IPO DateJul 12, 2017

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.
How it makes money
A short diagram of the business model.

Latest Documents

SEC Filings(384)

Expand
  • 8-KDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers05:00PM
  • 10-QQ3ended 30 Sept 202610 Nov
  • 8-KResults of Operations and Financial Condition10 Nov
  • S-3Registration statement (primary offering)4 Nov
  • DEF 14ADefinitive proxy statement26 Oct
  • PRE 14APreliminary proxy statement19 Oct
  • 8-KSubmission of Matters to a Vote of Security Holders15 Oct
  • 8-K/AEntry into a Material Definitive Agreement15 Oct
  • 8-KEntry into a Material Definitive Agreement13 Oct
  • 8-KSubmission of Matters to a Vote of Security Holders2 Oct
  • 8-KSubmission of Matters to a Vote of Security Holders25 Sep
  • PRE 14APreliminary proxy statement21 Sep
  • 8-KRegulation FD Disclosure16 Sep
  • 8-KOther Events16 Sep
  • 8-KOther Events15 Sep
  • Form 3Bohrer Daniel14 Sep
  • 8-KDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers4 Sep
  • DEFA14ADefinitive additional materials4 Sep
  • 8-KSubmission of Matters to a Vote of Security Holders4 Sep
  • EFFECTNotice of effectiveness2 Sep

News

  • Co-Diagnostics, Inc. (CODX) Q3 2026 Earnings Call Prepared Remarks Transcript10 Nov
  • Co-Diagnostics Reports Third Quarter 2026 Financial Results10 Nov
  • Co-Diagnostics Announces Updated Third Quarter 2026 Earnings Release Date and Webcast5 Nov
  • Co-Diagnostics to Participate in Three Global Tuberculosis Events in November as CoSara Advances Toward Anticipated India Launch5 Nov
  • Co-Diagnostics Announces Third Quarter 2026 Earnings Release Date and Webcast29 Oct
  • Co-Diagnostics' Joint Venture CoSara Diagnostics Announces Publication of Peer-Reviewed HPV Screening Study Using CoSara's SARAGENE® Test29 Oct
  • Co-Diagnostics' Joint Venture CoSara Diagnostics Completes Clinical Study and Regulatory Submission for Point-of-Care Tuberculosis Test, Sets Stage for Commercial Launch in India27 Oct
  • Co-Diagnostics' Joint Venture CoMira Diagnostics Invited by Saudi Ministry to Participate in Strategic Manufacturing Forum20 Oct
  • Co-Diagnostics Highlights PCR Platform Capabilities for Potential Plague Detection15 Oct
  • Co-Diagnostics Announces First Full Vector Smart® Laboratory Installation for Native American Tribe8 Oct
  • Co-Diagnostics Highlights Vector Smart® Momentum Following New Federal Initiative on Vector-Borne Disease7 Oct
  • Co-Diagnostics to Showcase Co-Dx PCR Platform* and MTB Test at WHX Labs Johannesburg, Highlight Ebola Assay Development6 Oct
  • Head to Head Review: Halozyme Therapeutics (NASDAQ:HALO) & Co-Diagnostics (NASDAQ:CODX)24 Sep
  • Co-Diagnostics to Participate in Global Health Events During UN General Assembly Week23 Sep
  • Co-Diagnostics to Participate in Global Health Roundtable on Ebola and Outbreak Innovation21 Sep
  • Co-Diagnostics to Participate in Joint WHO/Unitaid/UNAIDS Annual Consultation Meeting on September 17-18, 202617 Sep
  • Co-Diagnostics, Inc. (CODX) Shareholder/Analyst Call Transcript16 Sep
  • Co-Diagnostics and ReadyGo Collaborate to Evaluate Blood-Based Molecular Testing at the Point of Need, Starting with Ebola16 Sep
  • Co-Diagnostics to Hold Press Conference15 Sep
  • Co-Diagnostics Completes New Vector Smart® Laboratory Installations Amid Rising Dengue Activity in Florida10 Sep

Mentions in Filings

  • … etics SA); $244 million (Biodesix, Inc.); $157 million (Insight Molecular Diagnostics Inc.); $111 million (Exagen Inc.); $39 million (Burning Rock Biotech Limited); $9 million (Bionano Genomics, Inc.); and $3 million (<strong>Co-Diagnostics</strong>, Inc.). The median enterprise value observed for the selected companies was $111 million. Oppenheimer applied the median of the enterprise values derived from the selected companies, as adjusted by +/- 10%, then adde …
    Chemomab Therapeutics Ltd.Co-Diagnostics, Inc.·DEFM14A - Definitive proxy statement (merger)·Q4 26·30 Oct
  • … etics SA); $244 million (Biodesix, Inc.); $157 million (Insight Molecular Diagnostics Inc.); $111 million (Exagen Inc.); $39 million (Burning Rock Biotech Limited); $9 million (Bionano Genomics, Inc.); and $3 million (<strong>Co-Diagnostics</strong>, Inc.). The median enterprise value observed for the selected companies was $111 million. Oppenheimer applied the median of the enterprise values derived from the selected companies, as adjusted by +/- 10%, then adde …
    Snowdrift Parent CorpCo-Diagnostics, Inc.·S-4/A - Registration statement (business combination, amendment)·Q4 26·29 Oct
  • … etics SA); $244 million (Biodesix, Inc.); $157 million (Insight Molecular Diagnostics Inc.); $111 million (Exagen Inc.); $39 million (Burning Rock Biotech Limited); $9 million (Bionano Genomics, Inc.); and $3 million (<strong>Co-Diagnostics</strong>, Inc.). The median enterprise value observed for the selected companies was $111 million. Oppenheimer applied the median of the enterprise values derived from the selected companies, as adjusted by +/- 10%, then adde …
    Chemomab Therapeutics Ltd.Co-Diagnostics, Inc.·DRS - Draft registration statement·Q3 26·11 Aug
  • ?
    May 28, 2026 Dwight Egan President and Chief Executive Officer <strong>Co-Diagnostics, Inc.</strong> 2401 S. Foothill Drive Salt Lake City, Utah 84109 Re: Co-Diagnostics, Inc. Draft Registration Statement on Form S-3 Submitted May 22, 2026 CIK No. 0001692415 Dear Dwight Egan: This is to advise you that we do not intend to review your registration statement. We request that you publicly file your registration statement and non-public draft submission on EDGAR a …
    Co-Diagnostics, Inc.·LETTER - UPLOAD - Filing review upload·28 May·28 May
  • ?
    May 28, 2026 Dwight Egan President and Chief Executive Officer <strong>Co-Diagnostics, Inc.</strong> 2401 S. Foothill Drive Salt Lake City, Utah 84109 Re: Co-Diagnostics, Inc. Draft Registration Statement on Form S-3 Submitted May 22, 2026 CIK No. 0001692415 Dear Dwight Egan: This is to advise you that we do not intend to review your registration statement. We request that you publicly file your registration statement and non-public draft submission on ED …
    Co-Diagnostics, Inc.·TEXT-EXTRACT - UPLOAD - Filing review upload·28 May·28 May
  • … ly serves as Executive Vice President for Therapeutics MD. He served as Executive Vice President of MiMedx Group, Inc. (Nasdaq: MDGX) from April 2018 until December 2019. Mr. Borkowski also served as a director for <strong>Co-Diagnostics, Inc.</strong> (Nasdaq: CODX), from May 2017 until June 2019. Previously, he served as the Chief Financial Officer of Aceto Corporation (Nasdaq: ACET) from February 2018 to April 2018, and has held several executive positions wit …
    GridAI Technologies Corp.Co-Diagnostics, Inc.·10-K - Annual report FY 2025·FY25·1 May

Key Stats

Trading

Px/Chg 1D$1.09 / +0.93%
Avg Volume4.68M
Beta3.36
Mkt Cap6.82M
FD Mkt Cap1.35M

Float

Shrs Out/Float6.25M / 5.49M
Short Float0.12%
Days to Cover1.00
Stock Repurchased$0.00

Current Valuation

EV614.40K
EV/EBITDA-0.01
EV/Sales0.86
P/B0.42
P/S9.49
FCF Yield-117.22%
ROE-56.97%
ROA-42.51%
Current Ratio2.28

Estimates

P/E-0.14
Est P/E0.00
Est EPS-3.75
Est PEG0.00

Valuation

Metric5Yr AvgMay '23May '24May '25May '26Oct '26
PRICE-BASED RATIOS
Price / Earnings-1.01-2.91-1.01-0.28-0.08-0.75
Price / Sales12.791.215.262.718.0646.69
Price / Book Value0.300.360.420.200.100.42
Price / Free Cash Flow1.008.05-1.53-0.36-0.34-0.85
ENTERPRISE VALUE METRICS
Enterprise Value8.918.823.99.8-8.50.6
Enterprise Value / Sales-4.300.553.512.51-32.284.21
Enterprise Value / EBITDA-0.48-1.82-0.58-0.250.33-0.07
Enterprise Value / EBIT-0.43-1.62-0.56-0.250.32-0.07

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue-71.8%97.934.26.83.90.6
Gross Income-73.9%86.328.72.62.90.4
EBITDA—46.4-10.3-41.5-38.7-47.4
EBIT—46.1-11.6-42.7-40.1-48.5
Net Income—36.7-14.2-35.3-37.6-46.9
EPS (Diluted)—36.90-13.57-36.00-37.20-35.25
BALANCE SHEET
Cash & ST Inv-39.7%89.981.358.529.711.9
Total Assets-37.3%160.0123.195.364.024.7
Total Liabilities-36.7%25.68.69.39.74.1
Total Shareholder Equity-37.4%134.5114.586.054.320.6
CASH FLOW
Net Operating Cash Flow—41.16.6-22.1-29.2-29.1
Cap Ex1.1%-0.7-1.4-1.4-0.7-0.7
Free Cash Flow—40.45.1-23.4-29.9-29.8

Enterprise Value Bridge

Millions USD13 Nov '26
Price (As of 13 Nov '26)0.26
Basic Shares6.25
Market Cap1.6
Diluted Shares4.31
Fully Diluted Shares Outstanding4.31
Fully Diluted Market Cap1.1
+Consolidated Debt1.8
−In-the-Money Convertible Debt—
+Capital Leases1.8
+Operating Leases—
−Cash & Equivalents-3.6
−Short-term Investments-
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest-
+Pension Liabilities—
Enterprise Value-0.2

Segment data

Revenue

by Products and services

  • Product67%
  • Grant33%

Revenue

by Geography

  • United States93%
  • Non-us7%

Related companies

Apple Inc.

AAPL US

Kla Corp

KLAC US

Medtronic Public Limited Company

MDT US

Stryker Corp

SYK US

3M Company

MMM US

Northrop Grumman Corp /DE/

NOC US

Coherent Corp.

COHR US

Boston Scientific Corp

BSX US

Lenovo Group Ltd

LNVGY US

Garmin Ltd

GRMN US

HOYA Corporation

HOCPY US

Becton Dickinson & Co

0R19 LN

Co-Diagnostics, Inc. — Company Profile

Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.

Sector
Industrials
Industry
Commercial Services & Supplies
Exchange
UQ
CEO
Dwight Egan
Headquarters
Salt Lake City, UT, US
IPO Date
Jul 12, 2017
Employees
115
Website
co-dx.com

Key Metrics

Price
$1.09
Market Cap
$6.82M
Revenue (TTM)
$145.95K
Net Income (TTM)
$-9140038.00
EPS (TTM)
-4.06
P/E (TTM)
-0.14
P/B (TTM)
0.42
Dividend Yield
0.00%
ROE (TTM)
-56.97%
ROA (TTM)
-42.51%
Operating Margin
-63.09%
Beta
3.36

Dividends

Last Dividend
$0.00
Last Yield
0.00%

Summary

Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.

Website
co-dx.com
Location
Salt Lake City, UT, US
Phone801 438 1036
Employees115
CEODwight Egan
Sector
Industrials
Industry
Commercial Services & Supplies
IPO DateJul 12, 2017

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.
How it makes money
A short diagram of the business model.

Latest Documents

SEC Filings(384)

Expand
  • 8-KDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers05:00PM
  • 10-QQ3ended 30 Sept 202610 Nov
  • 8-KResults of Operations and Financial Condition10 Nov
  • S-3Registration statement (primary offering)4 Nov
  • DEF 14ADefinitive proxy statement26 Oct
  • PRE 14APreliminary proxy statement19 Oct
  • 8-KSubmission of Matters to a Vote of Security Holders15 Oct
  • 8-K/AEntry into a Material Definitive Agreement15 Oct
  • 8-KEntry into a Material Definitive Agreement13 Oct
  • 8-KSubmission of Matters to a Vote of Security Holders2 Oct
  • 8-KSubmission of Matters to a Vote of Security Holders25 Sep
  • PRE 14APreliminary proxy statement21 Sep
  • 8-KRegulation FD Disclosure16 Sep
  • 8-KOther Events16 Sep
  • 8-KOther Events15 Sep
  • Form 3Bohrer Daniel14 Sep
  • 8-KDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers4 Sep
  • DEFA14ADefinitive additional materials4 Sep
  • 8-KSubmission of Matters to a Vote of Security Holders4 Sep
  • EFFECTNotice of effectiveness2 Sep

News

  • Co-Diagnostics, Inc. (CODX) Q3 2026 Earnings Call Prepared Remarks Transcript10 Nov
  • Co-Diagnostics Reports Third Quarter 2026 Financial Results10 Nov
  • Co-Diagnostics Announces Updated Third Quarter 2026 Earnings Release Date and Webcast5 Nov
  • Co-Diagnostics to Participate in Three Global Tuberculosis Events in November as CoSara Advances Toward Anticipated India Launch5 Nov
  • Co-Diagnostics Announces Third Quarter 2026 Earnings Release Date and Webcast29 Oct
  • Co-Diagnostics' Joint Venture CoSara Diagnostics Announces Publication of Peer-Reviewed HPV Screening Study Using CoSara's SARAGENE® Test29 Oct
  • Co-Diagnostics' Joint Venture CoSara Diagnostics Completes Clinical Study and Regulatory Submission for Point-of-Care Tuberculosis Test, Sets Stage for Commercial Launch in India27 Oct
  • Co-Diagnostics' Joint Venture CoMira Diagnostics Invited by Saudi Ministry to Participate in Strategic Manufacturing Forum20 Oct
  • Co-Diagnostics Highlights PCR Platform Capabilities for Potential Plague Detection15 Oct
  • Co-Diagnostics Announces First Full Vector Smart® Laboratory Installation for Native American Tribe8 Oct
  • Co-Diagnostics Highlights Vector Smart® Momentum Following New Federal Initiative on Vector-Borne Disease7 Oct
  • Co-Diagnostics to Showcase Co-Dx PCR Platform* and MTB Test at WHX Labs Johannesburg, Highlight Ebola Assay Development6 Oct
  • Head to Head Review: Halozyme Therapeutics (NASDAQ:HALO) & Co-Diagnostics (NASDAQ:CODX)24 Sep
  • Co-Diagnostics to Participate in Global Health Events During UN General Assembly Week23 Sep
  • Co-Diagnostics to Participate in Global Health Roundtable on Ebola and Outbreak Innovation21 Sep
  • Co-Diagnostics to Participate in Joint WHO/Unitaid/UNAIDS Annual Consultation Meeting on September 17-18, 202617 Sep
  • Co-Diagnostics, Inc. (CODX) Shareholder/Analyst Call Transcript16 Sep
  • Co-Diagnostics and ReadyGo Collaborate to Evaluate Blood-Based Molecular Testing at the Point of Need, Starting with Ebola16 Sep
  • Co-Diagnostics to Hold Press Conference15 Sep
  • Co-Diagnostics Completes New Vector Smart® Laboratory Installations Amid Rising Dengue Activity in Florida10 Sep

Mentions in Filings

  • … etics SA); $244 million (Biodesix, Inc.); $157 million (Insight Molecular Diagnostics Inc.); $111 million (Exagen Inc.); $39 million (Burning Rock Biotech Limited); $9 million (Bionano Genomics, Inc.); and $3 million (<strong>Co-Diagnostics</strong>, Inc.). The median enterprise value observed for the selected companies was $111 million. Oppenheimer applied the median of the enterprise values derived from the selected companies, as adjusted by +/- 10%, then adde …
    Chemomab Therapeutics Ltd.Co-Diagnostics, Inc.·DEFM14A - Definitive proxy statement (merger)·Q4 26·30 Oct
  • … etics SA); $244 million (Biodesix, Inc.); $157 million (Insight Molecular Diagnostics Inc.); $111 million (Exagen Inc.); $39 million (Burning Rock Biotech Limited); $9 million (Bionano Genomics, Inc.); and $3 million (<strong>Co-Diagnostics</strong>, Inc.). The median enterprise value observed for the selected companies was $111 million. Oppenheimer applied the median of the enterprise values derived from the selected companies, as adjusted by +/- 10%, then adde …
    Snowdrift Parent CorpCo-Diagnostics, Inc.·S-4/A - Registration statement (business combination, amendment)·Q4 26·29 Oct
  • … etics SA); $244 million (Biodesix, Inc.); $157 million (Insight Molecular Diagnostics Inc.); $111 million (Exagen Inc.); $39 million (Burning Rock Biotech Limited); $9 million (Bionano Genomics, Inc.); and $3 million (<strong>Co-Diagnostics</strong>, Inc.). The median enterprise value observed for the selected companies was $111 million. Oppenheimer applied the median of the enterprise values derived from the selected companies, as adjusted by +/- 10%, then adde …
    Chemomab Therapeutics Ltd.Co-Diagnostics, Inc.·DRS - Draft registration statement·Q3 26·11 Aug
  • ?
    May 28, 2026 Dwight Egan President and Chief Executive Officer <strong>Co-Diagnostics, Inc.</strong> 2401 S. Foothill Drive Salt Lake City, Utah 84109 Re: Co-Diagnostics, Inc. Draft Registration Statement on Form S-3 Submitted May 22, 2026 CIK No. 0001692415 Dear Dwight Egan: This is to advise you that we do not intend to review your registration statement. We request that you publicly file your registration statement and non-public draft submission on EDGAR a …
    Co-Diagnostics, Inc.·LETTER - UPLOAD - Filing review upload·28 May·28 May
  • ?
    May 28, 2026 Dwight Egan President and Chief Executive Officer <strong>Co-Diagnostics, Inc.</strong> 2401 S. Foothill Drive Salt Lake City, Utah 84109 Re: Co-Diagnostics, Inc. Draft Registration Statement on Form S-3 Submitted May 22, 2026 CIK No. 0001692415 Dear Dwight Egan: This is to advise you that we do not intend to review your registration statement. We request that you publicly file your registration statement and non-public draft submission on ED …
    Co-Diagnostics, Inc.·TEXT-EXTRACT - UPLOAD - Filing review upload·28 May·28 May
  • … ly serves as Executive Vice President for Therapeutics MD. He served as Executive Vice President of MiMedx Group, Inc. (Nasdaq: MDGX) from April 2018 until December 2019. Mr. Borkowski also served as a director for <strong>Co-Diagnostics, Inc.</strong> (Nasdaq: CODX), from May 2017 until June 2019. Previously, he served as the Chief Financial Officer of Aceto Corporation (Nasdaq: ACET) from February 2018 to April 2018, and has held several executive positions wit …
    GridAI Technologies Corp.Co-Diagnostics, Inc.·10-K - Annual report FY 2025·FY25·1 May

Key Stats

Trading

Px/Chg 1D$1.09 / +0.93%
Avg Volume4.68M
Beta3.36
Mkt Cap6.82M
FD Mkt Cap1.35M

Float

Shrs Out/Float6.25M / 5.49M
Short Float0.12%
Days to Cover1.00
Stock Repurchased$0.00

Current Valuation

EV614.40K
EV/EBITDA-0.01
EV/Sales0.86
P/B0.42
P/S9.49
FCF Yield-117.22%
ROE-56.97%
ROA-42.51%
Current Ratio2.28

Estimates

P/E-0.14
Est P/E0.00
Est EPS-3.75
Est PEG0.00

Valuation

Metric5Yr AvgMay '23May '24May '25May '26Oct '26
PRICE-BASED RATIOS
Price / Earnings-1.01-2.91-1.01-0.28-0.08-0.75
Price / Sales12.791.215.262.718.0646.69
Price / Book Value0.300.360.420.200.100.42
Price / Free Cash Flow1.008.05-1.53-0.36-0.34-0.85
ENTERPRISE VALUE METRICS
Enterprise Value8.918.823.99.8-8.50.6
Enterprise Value / Sales-4.300.553.512.51-32.284.21
Enterprise Value / EBITDA-0.48-1.82-0.58-0.250.33-0.07
Enterprise Value / EBIT-0.43-1.62-0.56-0.250.32-0.07

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue-71.8%97.934.26.83.90.6
Gross Income-73.9%86.328.72.62.90.4
EBITDA—46.4-10.3-41.5-38.7-47.4
EBIT—46.1-11.6-42.7-40.1-48.5
Net Income—36.7-14.2-35.3-37.6-46.9
EPS (Diluted)—36.90-13.57-36.00-37.20-35.25
BALANCE SHEET
Cash & ST Inv-39.7%89.981.358.529.711.9
Total Assets-37.3%160.0123.195.364.024.7
Total Liabilities-36.7%25.68.69.39.74.1
Total Shareholder Equity-37.4%134.5114.586.054.320.6
CASH FLOW
Net Operating Cash Flow—41.16.6-22.1-29.2-29.1
Cap Ex1.1%-0.7-1.4-1.4-0.7-0.7
Free Cash Flow—40.45.1-23.4-29.9-29.8

Enterprise Value Bridge

Millions USD13 Nov '26
Price (As of 13 Nov '26)0.26
Basic Shares6.25
Market Cap1.6
Diluted Shares4.31
Fully Diluted Shares Outstanding4.31
Fully Diluted Market Cap1.1
+Consolidated Debt1.8
−In-the-Money Convertible Debt—
+Capital Leases1.8
+Operating Leases—
−Cash & Equivalents-3.6
−Short-term Investments-
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest-
+Pension Liabilities—
Enterprise Value-0.2

Segment data

Revenue

by Products and services

  • Product67%
  • Grant33%

Revenue

by Geography

  • United States93%
  • Non-us7%

Related companies

Apple Inc.

AAPL US

Kla Corp

KLAC US

Medtronic Public Limited Company

MDT US

Stryker Corp

SYK US

3M Company

MMM US

Northrop Grumman Corp /DE/

NOC US

Coherent Corp.

COHR US

Boston Scientific Corp

BSX US

Lenovo Group Ltd

LNVGY US

Garmin Ltd

GRMN US

HOYA Corporation

HOCPY US

Becton Dickinson & Co

0R19 LN